Idera Pharmaceuticals Inc. (NASDAQ:IDRA) Director Maxine Gowen bought 4,102 shares of Idera Pharmaceuticals stock in a transaction that occurred on Monday, October 3rd. The stock was purchased at an average cost of $2.56 per share, with a total value of $10,501.12. Following the completion of the transaction, the director now owns 10,543 shares of the company’s stock, valued at $26,990.08. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Idera Pharmaceuticals Inc. (NASDAQ:IDRA) traded up 2.35% on Wednesday, reaching $2.61. The company’s stock had a trading volume of 645,195 shares. The company’s market cap is $316.80 million. The company has a 50-day moving average price of $2.17 and a 200 day moving average price of $1.81. Idera Pharmaceuticals Inc. has a 12 month low of $1.19 and a 12 month high of $4.42.
Idera Pharmaceuticals (NASDAQ:IDRA) last posted its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.11). Idera Pharmaceuticals had a negative return on equity of 64.09% and a negative net margin of 6,169.32%. On average, equities research analysts anticipate that Idera Pharmaceuticals Inc. will post ($0.45) EPS for the current fiscal year.
Several research analysts recently commented on the company. Zacks Investment Research cut Idera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 4th. Wedbush reaffirmed an “outperform” rating and issued a $6.00 target price on shares of Idera Pharmaceuticals in a research report on Tuesday, August 2nd.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Alliancebernstein L.P. raised its position in Idera Pharmaceuticals by 19.8% in the second quarter. Alliancebernstein L.P. now owns 66,600 shares of the company’s stock valued at $102,000 after buying an additional 11,000 shares during the period. Rhumbline Advisers raised its position in Idera Pharmaceuticals by 1.0% in the second quarter. Rhumbline Advisers now owns 88,364 shares of the company’s stock worth $135,000 after buying an additional 860 shares during the last quarter. Creative Planning raised its position in Idera Pharmaceuticals by 11.8% in the second quarter. Creative Planning now owns 121,300 shares of the company’s stock worth $186,000 after buying an additional 12,800 shares during the last quarter. California State Teachers Retirement System raised its position in Idera Pharmaceuticals by 1.9% in the second quarter. California State Teachers Retirement System now owns 186,693 shares of the company’s stock worth $286,000 after buying an additional 3,478 shares during the last quarter. Finally, BlackRock Investment Management LLC raised its position in Idera Pharmaceuticals by 7.3% in the second quarter. BlackRock Investment Management LLC now owns 334,389 shares of the company’s stock worth $512,000 after buying an additional 22,791 shares during the last quarter. 28.44% of the stock is currently owned by hedge funds and other institutional investors.
Idera Pharmaceuticals Company Profile
Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.
Receive News & Ratings for Idera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.